Literature DB >> 17264539

Expansion of CD8+ cytotoxic T cells in vitro and in vivo using MHC class I tetramers.

Philip Savage1, Maggie Millrain, Sofia Dimakou, Justin Stebbing, Julian Dyson.   

Abstract

BACKGROUND: The expansion of cytotoxic CD8+ T lymphocytes (CTLs) which recognize peptide epitopes of tumour or viral origin has been a major aim of immunotherapy research for the past decade. Alongside the established dendritic cell-based methods, more recent approaches using recombinant MHC class I peptide complexes have been developed.
METHODS: In this study we have explored the potential of a simplified system using soluble streptavidin-linked MHC class I tetramers to expand antigen-specific CTLs in vitro and in vivo.
RESULTS: In vitro tetramer-mediated expansion of CD8+ CTLs recognizing HLA-2/Melan-A and HLA-A2/Gag complexes was demonstrated with PBMCs from healthy donors or HIV+ donors, respectively. With 3 weekly rounds of tetramer stimulation, cell numbers expanded 100-fold from 0.05 to 5.0%. The lytic function of HLA-A2/Melan-A-expanded cells was demonstrated in 51Cr release assays by specific killing of T2 cells pulsed with Melan-A, but not other peptides. Similarly, murine CD8+ T cells specific for the HY epitope H2-Db/Uty could be expanded in vitro over a wide range of tetramer concentrations (0.008-1.0 microg/ml), with a single exposure producing substantial T cell expansion from 0.11 to 36%. Intraperitoneal administration of H2-Db/Uty tetramers to primed C57BL/6 mice produced over 5-fold expansion of Db/Uty-specific CTL in vivo.
CONCLUSION: The results in this paper demonstrate that simple, multimeric MHC complexes may be of value in expanding CTLs in vitro for adoptive immunotherapy and also potentially in vivo. Further studies will be necessary to clarify the optimum protocols and schedules of administration for T cell expansion using recombinant MHC multimers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17264539     DOI: 10.1159/000099152

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  12 in total

1.  Controlled major histocompatibility complex-T cell receptor signaling allows efficient generation of functional, antigen-specific CD8+ T cells from embryonic stem cells and thymic progenitors.

Authors:  Jian Lin; Hui Nie; Phillip W Tucker; Krishnendu Roy
Journal:  Tissue Eng Part A       Date:  2010-09       Impact factor: 3.845

2.  Permanent silencing of NKG2A expression for cell-based therapeutics.

Authors:  Constança Figueiredo; Axel Seltsam; Rainer Blasczyk
Journal:  J Mol Med (Berl)       Date:  2008-11-11       Impact factor: 4.599

3.  In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.

Authors:  Stefano Ugel; Alessia Zoso; Carmela De Santo; Yu Li; Ilaria Marigo; Paola Zanovello; Elisa Scarselli; Barbara Cipriani; Mathias Oelke; Jonathan P Schneck; Vincenzo Bronte
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

4.  Molecular factors in dendritic cell responses to adsorbed glycoconjugates.

Authors:  Nathan A Hotaling; Richard D Cummings; Daniel M Ratner; Julia E Babensee
Journal:  Biomaterials       Date:  2014-04-16       Impact factor: 12.479

5.  Generation of functional, antigen-specific CD8+ human T cells from cord blood stem cells using exogenous Notch and tetramer-TCR signaling.

Authors:  Irina Fernandez; Tracy P Ooi; Krishnendu Roy
Journal:  Stem Cells       Date:  2014-01       Impact factor: 6.277

Review 6.  Soluble MHC class I complexes for targeted immunotherapy.

Authors:  Anna Schappert; Jonathan P Schneck; Lauren Suarez; Mathias Oelke; Christian Schütz
Journal:  Life Sci       Date:  2018-08-10       Impact factor: 5.037

7.  MHC-Ig induces memory T cell formation in vivo and inhibits tumour growth.

Authors:  Christian Schütz; Alessia Zoso; Shiwen Peng; Jonathon D Bennett; Jonathan P Schneck; Mathias Oelke
Journal:  Immun Inflamm Dis       Date:  2014-11-11

8.  Identification of apoB-100 Peptide-Specific CD8+ T Cells in Atherosclerosis.

Authors:  Paul C Dimayuga; Xiaoning Zhao; Juliana Yano; Wai Man Lio; Jianchang Zhou; Peter M Mihailovic; Bojan Cercek; Prediman K Shah; Kuang-Yuh Chyu
Journal:  J Am Heart Assoc       Date:  2017-07-15       Impact factor: 5.501

9.  One-pot, mix-and-read peptide-MHC tetramers.

Authors:  Christian Leisner; Nina Loeth; Kasper Lamberth; Sune Justesen; Christina Sylvester-Hvid; Esben G Schmidt; Mogens Claesson; Soren Buus; Anette Stryhn
Journal:  PLoS One       Date:  2008-02-27       Impact factor: 3.240

10.  Induction of tolerance against the arthritogenic antigen with type-II collagen peptide-linked soluble MHC class II molecules.

Authors:  Yoon-Kyung Park; Sundo Jung; Se-Ho Park
Journal:  BMB Rep       Date:  2016-06       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.